Generic vonoprazan put to the test against Brand-Name voquezna

NCT ID NCT07278349

Completed Knowledge-focused Sponsor: Humanis Saglık Anonim Sirketi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared a generic vonoprazan 20 mg tablet to the brand-name Voquezna in 28 healthy adults. Participants took a single dose of each under fasting conditions to see if the generic releases the same amount of drug into the bloodstream. The goal was to check bioequivalence, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vonoprazan
What this could lead to: If successful, this could help bring a lower-cost generic version of vonoprazan to market for treating stomach acid conditions.
What could go wrong: This is a small, early-phase study in healthy volunteers, not patients. It only checks if the drug levels match, not whether it actually treats disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EROSIVE ESOPHAGITIS(EE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophagitis gastritis Helicobacter pylori infectious disease peptic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EROSIVE ESOPHAGITIS(EE) EROSIVE GASTRITIS HELICOBACTER PYLORI INFECTIONS

Contacts and locations

Locations

IPRC International Pharmaceutical Research Center

Amman, Sport City Circle, 11196, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.